Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Disease Awareness Ads Indistinct From Product Ads Could Be Viewed As Promotional, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Non-branded ads should be “separate and distinct” from product-specific ads, FDA Regulatory Counsel Kristin Davis says.

You may also be interested in...



FDA Extends Comment Period For Direct-To-Consumer Advertising Guidances

The agency has reopened the comment period until Aug. 10 to allow additional time for conducting DTC research, Ad Division Director Tom Abrams says. FDA plans to conduct its own research on the content and format of the brief summary.

Alternatives To Brief Summary Outlined In Draft Guidance

One of FDA's three draft guidances on DTC advertising requests that consumer-friendly language be used. Commissioner McClellan calls proposed brief summary alternatives a "win-win" and suggests manufacturers will be able to reduce their advertising costs as a result.

U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says

The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel